pSivida Corp. (PSDV) Reports a Q1 Loss
More News related to PSDV
- pSivida Corp. Announces First Quarter 2010 Financial Results Release Date and Conference Call Information
- pSivida Announces Completion of BrachySil(TM) Dose Ranging Study in Pancreatic Cancer
- pSivida Announces Last Patient in Phase III Iluvien(R) Trial Completes 2 Year Follow-Up Visit
- pSivida (PSDV) Reports Safety and Efficacy Results from 18-Month Interim Readout of Human PK Iluvien Study
- pSivida Reports Safety and Efficacy Results from 18-Month Interim Readout of Human PK Iluvien(R) Study
More News related to Earnings
- Sprint Nextel (S) Aims to Reduce Labor Costs by $350M in Q409
- Highlights From DISH's Q3 Conference Call - Q&A Session
- Adams Resources & Energy (AE) Announces Activity At Haynesville Shale
- NCI Building Systems (NCS) Announces Put Option Notification for 2.125% Convertible Senior Subordinated Notes
- Novartis (NVS) Acquires Majority Stake in Zhejiang Tianyuan Bio-Pharmaceutical for $125 Million
pSivida Corp. (NASDAQ: PSDV) reports a Q1 loss of $0.03 compared to a loss of $0.04 for the same period last year.
Revenues for the three months ended September 30, 2008 were $2.8 million compared to revenues of $103,000 for the comparable period of the prior fiscal year. Current quarter revenues were predominantly related to the Company's March 2008 amended collaboration agreement with Alimera Sciences, Inc.
"With cash of approximately $11.0 million at September 30, 2008, no debt, our current collaboration and licensing agreements and an expected filing of the NDA for Iluvien in early 2010, we believe we can fund our operations as currently conducted without accessing the capital markets through to receipt of the $25m milestone payment that is due if Iluvien is approved by the FDA."
pSivida Corp., formerly pSivida Limited., is a drug delivery company committed to the biomedical sector, with a primary focus on ophthalmology and oncology. [SM]
Related Categories
EarningsStocks Mentioned
+0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
